Becker-Cohen M - Search Results

1

Rapid home therapy infusion of velaglucerase alfa in naïve patients with Gaucher disease.

Becker-Cohen M, Revel-Vilk S, Frydman D, Dinur T, Tiomkin M, Istaiti M, Arbel N, Bauer P, Cozma C, Rolfs A, Szer J, Zimran A. Becker-Cohen M, et al. Intern Med J. 2024 Mar;54(3):398-403. doi: 10.1111/imj.16179. Epub 2023 Jul 26. Intern Med J. 2024. PMID: 37493453

2

Glucosylsphingosine is a reliable response biomarker in Gaucher disease.

Arkadir D, Dinur T, Revel-Vilk S, Becker Cohen M, Cozma C, Hovakimyan M, Eichler S, Rolfs A, Zimran A. Arkadir D, et al. Am J Hematol. 2018 Jun;93(6):E140-E142. doi: 10.1002/ajh.25074. Epub 2018 Mar 15. Am J Hematol. 2018. PMID: 29473199 Free article. No abstract available.

3

Rapid intravenous infusion of velaglucerase-alfa in adults with type 1 Gaucher disease.

Zimran A, Revel-Vilk S, Becker-Cohen M, Chicco G, Arbel N, Rolfs A, Szer J. Zimran A, et al. Am J Hematol. 2018 Sep;93(9):E246-E248. doi: 10.1002/ajh.25205. Epub 2018 Aug 9. Am J Hematol. 2018. PMID: 29989200 Free article. No abstract available.

4

Prodromal substantia nigra sonography undermines suggested association between substrate accumulation and the risk for GBA-related Parkinson's disease.

Arkadir D, Dinur T, Becker Cohen M, Revel-Vilk S, Tiomkin M, Brüggemann N, Cozma C, Rolfs A, Zimran A. Arkadir D, et al. Eur J Neurol. 2019 Jul;26(7):1013-1018. doi: 10.1111/ene.13927. Epub 2019 Mar 1. Eur J Neurol. 2019. PMID: 30714262

5

Glucosylsphingosine (lyso-Gb1) as a Biomarker for Monitoring Treated and Untreated Children with Gaucher Disease.

Hurvitz N, Dinur T, Becker-Cohen M, Cozma C, Hovakimyan M, Oppermann S, Demuth L, Rolfs A, Abramov A, Zimran A, Revel-Vilk S. Hurvitz N, et al. Int J Mol Sci. 2019 Jun 21;20(12):3033. doi: 10.3390/ijms20123033. Int J Mol Sci. 2019. PMID: 31234327 Free PMC article.

6

Long Term Follow-Up of 103 Untreated Adult Patients with Type 1 Gaucher Disease.

Dinur T, Zimran A, Becker-Cohen M, Arkadir D, Cozma C, Hovakimyan M, Oppermann S, Demuth L, Rolfs A, Revel-Vilk S. Dinur T, et al. J Clin Med. 2019 Oct 11;8(10):1662. doi: 10.3390/jcm8101662. J Clin Med. 2019. PMID: 31614613 Free PMC article.

7

Macular Ganglion Cell Complex and Peripapillary Retinal Nerve Fiber Layer Thinning in Patients with Type-1 Gaucher Disease.

Weill Y, Zimran A, Zadok D, Wasser LM, Revel-Vilk S, Hanhart J, Dinur T, Arkadir D, Becker-Cohen M. Weill Y, et al. Int J Mol Sci. 2020 Sep 24;21(19):7027. doi: 10.3390/ijms21197027. Int J Mol Sci. 2020. PMID: 32987733 Free PMC article.

8

Patient reported outcome measures in a large cohort of patients with type 1 Gaucher disease.

Dinur T, Istaiti M, Frydman D, Becker-Cohen M, Szer J, Zimran A, Revel-Vilk S. Dinur T, et al. Orphanet J Rare Dis. 2020 Oct 13;15(1):284. doi: 10.1186/s13023-020-01544-z. Orphanet J Rare Dis. 2020. PMID: 33050940 Free PMC article.

9

Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data.

Istaiti M, Revel-Vilk S, Becker-Cohen M, Dinur T, Ramaswami U, Castillo-Garcia D, Ceron-Rodriguez M, Chan A, Rodic P, Tincheva RS, Al-Hertani W, Lee BH, Yang CF, Kiec-Wilk B, Fiumara A, Rubio B, Zimran A. Istaiti M, et al. Am J Hematol. 2021 May 1;96(5):545-551. doi: 10.1002/ajh.26131. Epub 2021 Mar 11. Am J Hematol. 2021. PMID: 33606887 Free article.

10

Parkinson's Clustering in Families of Non-Neuronopathic N370S GBA Mutation Carriers Indicates the Presence of Genetic Modifiers.

Dinur T, Becker-Cohen M, Revel-Vilk S, Zimran A, Arkadir D. Dinur T, et al. J Parkinsons Dis. 2021;11(2):615-618. doi: 10.3233/JPD-202422. J Parkinsons Dis. 2021. PMID: 33612495

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

34 results

Search Page

Filters